Manager TitleAgeSince
President 42 -
Corporate Secretary - -
Treasurer 60 -
Director TitleAgeSince
Director/Board Member 42 -
Date Insider Type Main position Quantity % Market Cap.
28/07/20Tender

Chief Executive Officer

21,978 0.3026%
28/07/20Tender

Chief Financial Officer

6,239 0.0859%
28/07/20Tender

Chairman

2,135 0.0294%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-10.93% - - 16.07M
+2.96%+3.01%+59.87%+173.31% 1,070B
+3.05%+5.23%+72.11%+67.81% 624B
-0.04%+1.20%+35.72%+87.93% 450B
+2.14%-2.07%+27.62%+22.57% 328B
+1.87%+1.87%+40.58%+42.08% 292B
+1.36%+0.17%+29.90%+49.33% 284B
+1.98%+4.08%-25.78%-39.02% 217B
+0.45%+1.65%+25.65%+68.35% 198B
+5.21%+7.93%+21.99%+83.23% 161B
Average +2.02%+0.98%+31.96%+61.73% 402.71B
Weighted average by Cap. +2.36%+0.70%+43.48%+88.16%
Logo Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.
Employees
-